Palvella Therapeutics, Inc.
PVLAHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframePalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company carries a $1.50B market cap, placing it firmly in the small-cap category. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Market Cap
$1.50B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-15.67
EPS (TTM)
$-4.17
EPS (Fwd)
$-6.68
ROE
-34.3%
ROA
-16.6%
Cash
$261.9M
Total Debt
$20.4M
Free CF
-$21.6M
52W Change
339.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $261.9M in cash comfortably exceeding the $20.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$21.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -34.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PVLA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.